- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00629447
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Study Overview
Detailed Description
Many patients with brain tumors develop thinning of the bones and weak bones, called osteoporosis. At baseline (or within 4 weeks of enrollment onto study) and 12 months the subject will have a bone densitometry study (DEXA-Scan) which is a test to determine bone density (the measure of the strength and thickness of bones) by using x-ray techniques.
A single arm pilot trial will be performed with newly diagnosed pathologically confirmed malignant glioma patients. The patients will receive low molecular weight heparin (Tinzaparin), which will begin at least 48 hours after craniotomy or stereotactic biopsy, but no later than four weeks after the most recent surgery.
The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
The primary analysis will be conducted at six months and the safety will be determined by the incidence of clinically significant bleeding, ≥ grade III/IV CNS hemorrhage or grade II hemorrhage elsewhere. The Tinzaparin will be discontinued for any grade II or higher hemorrhage, except CNS hemorrhage and patients with asymptomatic CNS hemorrhage seen on a scan (grade III) at study entry will stay on Tinzaparin, except if the CNS hemorrhage expands or there is a new hemorrhage, in which case the Tinzaparin will be discontinued. For patients without a CNS hemorrhage at entry, a new asymptomatic CNS hemorrhage (grade III), or a CNS hemorrhage with symptoms (≥ grade IV) will result in discontinuation of the Tinzaparin. If the patient does not have any hemorrhage, the Tinzaparin will be continued for an additional six months with the second analysis performed at 12 months. Patients may stay on Innohep as long as they are benefiting and there are no adverse reactions necessitation stopping therapy. Patients will continue to having the same labs and clinical follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health Systems
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with newly diagnosed pathologically confirmed WHO Grade III or Grade IV glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed glioma, gliosarcoma and glioblastoma multiforme);
- Patients must be 18 years of age or older at the time of informed consent;
- Karnofsky performance status 60% and a life expectancy of at least 6 months;
- The patient is at least 48 hours after craniotomy or stereotactic biopsy but no later than four weeks from the last surgical procedure;
- Adequate hematologic function as demonstrated by laboratory values performed within 14 days: platelet count > 100,000, prothrombin time (PT) 1.2 x control, inactivated partial thromboplastin time (aPTT) 1.2 x control;
- Signed informed consent prior to patient registration.
Exclusion Criteria:
- Presence of a coagulopathy, as defined by laboratory parameters including a platelet count < 100,000, PT > 1.2 x control or a PTT > 1.2 x control.
- Symptomatic intracranial bleeding, which includes inter- or intratumor bleeding and causes mass effect or neurological disability control;
- The presence of acute or chronic deep venous thrombosis demonstrated by ultrasonography or venography. A baseline screening ultrasound or venogram is not required;
- Active systemic bleeding, such as gastrointestinal bleeding or gross hematuria;
- Excessive risk of bleeding as defined by stroke within the prior 6 months, history of CNS or intraocular bleed, or septic endocarditis;
- Prior history of documented DVT or PE;
- History of immune mediated heparin induced thrombocytopenia, as documented by a platelet count < 50,000 and positive heparin-induced platelet aggregation test;
- Contraindication to tinzaparin or other heparins, including allergy or hypersensitivity to heparin or pork products, sulfite allergy, benzyl alcohol allergy or have or had had an epidural catheter or traumatic spinal puncture within 7 days prior to screening;
- Serum creatinine >3.0 mg/dl;
- Patient or partner of childbearing potential and not using adequate contraception;
- Pregnant or nursing (women of childbearing potential may have a screening pregnancy test at the discretion of the investigator);
- Medical condition requiring long-term anticoagulants such as atrial fibrillation or a mechanical heart valve;
- Inability to give informed consent;
- Inability to comply with study procedures, including subcutaneous injections and diagnostic procedures;
- Participating in another study of an investigational agent at the time of enrollment. The use of an experimental or investigational regimen of an approved product is not cause for exclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
|
The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Neurologic evaluation, CBC, Coagulation test (PT w/ INR, aPTT),Karnofsky performance status, Thrombosis panel, Adverse events assessment
Time Frame: MONTHS 2, 4, 6, 9, 12
|
MONTHS 2, 4, 6, 9, 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bone densitometry study (DEXA-Scan)d
Time Frame: baseline and 12 months
|
baseline and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James Vredenburgh, MD, Duke University Heatlh Systems
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Embolism and Thrombosis
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Neoplasms
- Thromboembolism
- Venous Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Tinzaparin
Other Study ID Numbers
- Pro00008486
- 4930 (Other Identifier: SMC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Brain Tumor
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
University of MiamiRecruitingGlioma | Brain Tumor | Malignant Glioma | Primary Brain Tumor | Malignant Primary Brain TumorUnited States
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
-
Pietro Mortini, MD, Prof.RecruitingBrain Tumor, Primary | Brain Tumor - MetastaticItaly
-
University of Michigan Rogel Cancer CenterTerminated
-
Shanghai Henlius BiotechRecruiting
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
GuerbetRecruitingBrain Tumor, Recurrent | Brain Tumor, PrimaryItaly, Hungary, Poland
-
Duke UniversityTerminated
Clinical Trials on Innohep
-
Assistance Publique - Hôpitaux de ParisLEO PharmaCompletedAnemia | Acute Chest Syndrome | Sickle Cell | Low-Molecular-Weight HeparinFrance
-
University of AarhusAarhus University Hospital; LEO PharmaCompletedFetal Growth RetardationDenmark
-
LEO PharmaCompletedDeep Vein ThrombosisBulgaria, Croatia, Czechia, France, Germany, Poland, Romania, Serbia, Spain
-
Galician Research Group on Digestive TumorsLEO PharmaRecruitingThromboembolism | Colorectal Cancer MetastaticSpain
-
Ottawa Hospital Research InstituteCompletedAdenocarcinoma of the ColonCanada, France, Belgium
-
King Saud UniversityKing AbdulAziz City for Science and TechnologyUnknownBleeding | Venous ThromboembolismSaudi Arabia
-
Maisonneuve-Rosemont HospitalCompletedRenal Insufficiency, Chronic | Deep Venous Thrombosis, Protection AgainstCanada
-
University of CalgaryLEO PharmaCompletedVenous ThromboembolismCanada
-
St. Joseph's Healthcare HamiltonLEO Pharma; Heart and Stroke Foundation of OntarioTerminatedVenous Thrombosis | Pulmonary EmbolismCanada
-
Ottawa Hospital Research InstituteLEO PharmaCompletedCancer | Deep Vein Thrombosis | Pulmonary EmbolismCanada